Mad Money Mailbag: Avon's No A-Lister

Cramer encourages a viewer to look past the cosmetics company. Also, why Cramer likes Amgen.
Author:
Publish date:

Editor's Note: The following are questions received from viewers of "Mad Money," seen every day at 6 p.m. EDT on CNBC.

I'm looking to move some money out of CDs. Where do you think Avon Products (AVP) - Get Report is headed?-- Peggy from North Carolina

James J. Cramer:

Even though I like the current growth prospects in Latin America, where the company has a sizable presence, I believe that investors should focus elsewhere. The cosmetics companies all have been struggling of late as consumer giants like

Procter & Gamble

(PG) - Get Report

are gradually exerting their size across every major category.

What is your take on Amgen (AMGN) - Get Report? Can it reach $90 a share?-- Adrian from California

James J. Cramer:

Amgen remains one of my favorite biotech stocks in the market. The company has a better pipeline than any major drugmaker out there, yet better earnings visibility than the smaller biotech firms can offer. With that in mind, I do believe that Amgen could eventually trade up toward $90.

Want more Cramer? Check out Jim's rules and commandments for investing from his latest book by

clicking here

. Learn how to become a better investor. Get started now with the investing rules that Cramer lays out: